ConductScience.org, home

Library / Genes

PIK3CB: phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta

1 protein, 80 patents, 33 drugs, 218 trials, 2,960 NIH grants and 15,327 papers.

Gene 7

Its symbol and name are HGNC's, unless HGNC and NCBI Gene contradict each other.

FieldValueSource
SymbolPIK3CBHGNC
Namephosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit betaHGNC
NCBI Gene ID5291NCBI Gene
HGNC IDHGNC:8976HGNC
EnsemblENSG00000051382NCBI Gene
AliasesP110BETA, PI3K, PI3KBETA, PIK3C1NCBI Gene
Typeprotein-codingNCBI Gene

Proteins 1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated inSource
P42338Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform1,0700Ensembl, GeneID, HGNCUniProt

Patents 80

Patents whose sequence listing holds the protein exactly: the same sequence, by SHA-256, length and CRC-64. A sequence a patent lists is not always one it claims.

PublicationPublishedSEQ ID NOProteinSource
WO 2026013052 A12026-01-152P42338Espacenet
EP 4641201 A22025-10-292960P42338Espacenet
JP 2025532979 A2025-10-03299P42338Espacenet
EP 4593850 A22025-08-06299P42338Espacenet
JP 2025517969 A2025-06-122960P42338Espacenet
WO 2025101914 A12025-05-155P42338Espacenet
US 12295971 B22025-05-13299P42338Espacenet
JP 2024123008 A2024-09-107602P42338Espacenet
JP 2024123008 A2024-09-107605P42338Espacenet
US 11708396 B22023-07-251841P42338Espacenet

Drugs 33

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
APITOLISIBCHEMBL1922094PI3-kinase class I inhibitorINHIBITORChEMBL
AZD-6482CHEMBL2165191PI3-kinase class I inhibitorINHIBITORChEMBL
AZD-8186CHEMBL3408248PI3-kinase p110-beta subunit inhibitorINHIBITORChEMBL
BAY-1082439CHEMBL3644672PI3-kinase p110-beta subunit inhibitorINHIBITORChEMBL
BGT-226CHEMBL3545096PI3-kinase class I inhibitorINHIBITORChEMBL
BGT-226 FREE BASECHEMBL3218578PI3-kinase class I inhibitorINHIBITORChEMBL
BUPARLISIBCHEMBL2017974PI3-kinase class I inhibitorINHIBITORChEMBL
DACTOLISIBCHEMBL1879463PI3-kinase class I inhibitorINHIBITORChEMBL
DS-7423CHEMBL3545248PI3-kinase class I inhibitorINHIBITORChEMBL
FIMEPINOSTATCHEMBL3622533PI3-kinase p110-beta subunit inhibitorINHIBITORChEMBL

Trials 218

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT07447076PAXALISIBPHASE2ClinicalTrials.gov
NCT07391215PAXALISIBPHASE1/PHASE2ClinicalTrials.gov
NCT07287202PAXALISIBPHASE1/PHASE2ClinicalTrials.gov
NCT06757634GEDATOLISIBPHASE3ClinicalTrials.gov
NCT06208657PAXALISIBPHASE1/PHASE2ClinicalTrials.gov
NCT06190899GEDATOLISIBPHASE1/PHASE2ClinicalTrials.gov
NCT05971758FIMEPINOSTATPHASE2ClinicalTrials.gov
NCT05501886GEDATOLISIBPHASE3ClinicalTrials.gov
NCT05183204PAXALISIBPHASE2ClinicalTrials.gov
NCT05009992PAXALISIBPHASE2ClinicalTrials.gov

NIH grants 2960

NIH projects whose papers are about the gene, through NIH's grant-paper links.

ProjectTitleIts papers about the geneNewest fiscal yearSource
P30CA008748Cancer Center Support Grant742,025NIH's project files
P30CA016672Cancer Center Support Grant612,025NIH's project files
P50CA168504Dana Farber/Harvard Cancer Center Specialized Program of Research Excellence in Breast Cancer142,025NIH's project files
P30CA068485Cancer Center Support Grant132,025NIH's project files
P30CA006973Regional Oncology Research Center112,025NIH's project files
P30CA013330Cancer Center Support Grant112,025NIH's project files
R35CA210057Integrating targeted therapy and immunotherapy to break through cancer102,025NIH's project files
P30CA125123Baylor College of Medicine Cancer Center - Cancer Center Support Grant92,025NIH's project files
P50CA092629SPORE in Prostate Cancer92,025NIH's project files
P50CA165962Targeted Therapies for Glioma82,025NIH's project files

Papers 15327

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

PMIDFound bySource
42827142PubTator, text miningPubMed
42826912PubTator, text miningPubMed
42826809PubTator, text miningPubMed
42826660PubTator, text miningPubMed
42825353PubTator, text miningPubMed
42825310PubTator, text miningPubMed
42824816PubTator, text miningPubMed
42823681PubTator, text miningPubMed
42823563PubTator, text miningPubMed
42823400PubTator, text miningPubMed

The same record as JSON

Release gene-search-2026-11-11-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ChEMBL, through Open Targets: CC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

EMBL-EBI's patent proteins: EMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use

GenBank's patent files: GenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/

HGNC: CC0: https://www.genenames.org/about/license/

NCBI Gene: None named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/

NIH's project files and grant-paper links: Public domain (NIH RePORTER)

Open Targets: CC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

PubTator 3: Public domain

UniProt: CC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license